Navitoclax (ABT-263)
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Navitoclax (ABT-263), covering 2010-11-09 to 2016-11-02. Get the full timeline:
Most recent: Clinical Trial Update: A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL) [Phase 2]